To test the oncogenic activity of the MSI2-HOXA9 fusion, we generated an MSI2-HOXA9 gene reflecting the breakpoint reported in CML patients (t(7:17)(p15;q23)). The gene discussed is HOXA9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.